SERVICES

Archive | Oregon

Business, entertainment, technology, financial and regional event news from Oregon (Ore.), USA.

Paragon BioTeck, Inc.

Paragon BioTeck to Attend 34th Annual J.P. Morgan Healthcare Conference

PORTLAND, Ore., Jan. 7, 2016 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held pharmaceutical and medical device company, will sponsor a special reception during the J.P. Morgan 2016 Healthcare Conference, being held in San Francisco, January 11-14. The conference, which is now in its 34th year, is an invitation-only event intended to create an […]

Continue Reading
Huamei hospital

Hospital Founder Dr. Edward Reed Wagner (1862 to 1943) Honored in China

CANBY, Ore., Nov. 17, 2015 (SEND2PRESS NEWSWIRE) — Dr. Craig Wagner Shinn announces that his great grandfather Dr. Edward Reed Wagner, a missionary doctor in the American Board of Commissioners of Foreign Missions (Global Ministries) in the late 19th century, was honored for founding Huamei Hospital in Linqing, Shandong, China at a special ceremony celebrating […]

Continue Reading
Going to Bed is Easy Now

Mother-Daughter Team Releases Children’s Book Designed to Delight Parents, Typically Developing Kids, and those with ADD/ADHD or Autism Spectrum

PORTLAND, Ore., May 7, 2015 (SEND2PRESS NEWSWIRE) — Sherwood, Oregon based publisher, Journey Books, LLC, releases ‘Going to Bed is Easy Now’ (ISBN: 978-0692357842), first in series of illustrated children’s books by Doris and Maritsa Bowman. Written in both English and Spanish, the book is designed to ease the stress of everyday activities that create […]

Continue Reading
Comfortear Lacrisolve

Paragon BioTeck Receives CE Mark Approval on Comfortear Lacrisolve Absorbable Punctum Plug

PORTLAND, Ore., Nov. 17, 2014 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held biopharmaceutical and medical device company specializing in the development of ophthalmic pharmaceuticals, devices and therapies, announced today that it has received CE mark approval for the recently FDA cleared Comfortear(R) Lacrisolve(TM) Absorbable Punctum Plug. CE mark approval is recognized and associated […]

Continue Reading
Comfortear Lacrisolve

Paragon BioTeck, Inc. Announces Corporate Citizenship Initiative, ‘Paragon Gives’

PORTLAND, Ore., Oct. 16, 2014 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held biopharmaceutical and medical device company specializing in the development of ophthalmic pharmaceuticals, devices and therapies, announces that it will be formally launching its corporate citizenship initiative coined, Paragon Gives. On Sunday October 19, 2014, Paragon BioTeck, will kick off its newly […]

Continue Reading
ophthalmic pharmaceuticals

Paragon BioTeck to Exhibit at American Academy of Ophthalmology Annual Meeting in Chicago

PORTLAND, Ore., Oct. 15, 2014 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held biopharmaceutical and medical device company specializing in the development of ophthalmic pharmaceuticals, devices and therapies, will be exhibiting at the American Academy of Ophthalmology (Booth #4550) in Chicago, Ill., on October 18 – 21.

Continue Reading
Comfortear Lacrisolve

Paragon BioTeck, Inc. Receives FDA Clearance for Comfortear Lacrisolve Absorbable Punctum Plug

PORTLAND, Ore., June 25, 2014 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held biopharmaceutical and medical device company specializing in the development of ophthalmic pharmaceuticals, devices and therapies, announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Comfortear(R) Lacrisolve(TM) Absorbable Punctum Plug.

Continue Reading
Ophthalmic Solution

Paragon BioTeck announces FDA Approved Phenylephrine Hydrochloride Ophthalmic Solution Readily Available

PORTLAND, Ore., June 4, 2014 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held U.S. biopharmaceutical company specializing in the development of ophthalmic pharmaceuticals and therapies, announces its FDA approved Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5 percent and 10 percent, to dilate the pupil, is readily available through Bausch + Lomb or your primary wholesaler.

Continue Reading
Ophthalmic

Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5 percent and 10 percent Readily Available

PORTLAND, Ore., April 9, 2014 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held biopharmaceutical company specializing in the development of ophthalmic pharmaceuticals and therapies, received FDA approval of Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5 percent and 10 percent, to dilate the pupil on March 21, 2013.

Continue Reading
Ilast ocular care

Paragon Puts Ilast Center Stage

PORTLAND, Ore., Nov. 8, 2013 (SEND2PRESS NEWSWIRE) — Leading biopharmaceutical company Paragon BioTeck, Inc. announced today that it plans to launch its new line of products, known as Ilast(R), at the Annual American Academy of Ophthalmology meeting in New Orleans. Paragon signed an exclusive distribution agreement with Horus Pharma to supply Ilast(R) ocular care products […]

Continue Reading

Part of the Neotrope® News Network, USA. Neotrope.net